Savana Secures Series B Funding Led by Cathay Innovation to Expand in America
Savana, the healthtech startup accelerating health science with big data, announced the successful completion of its $15 million B Series led by Cathay Innovation. Other investors include Seaya Ventures, the lead investor in the previous $5 million round, as well as new investors, such as MACSF, the French mutual insurer for health professionals.
Savana develops artificial intelligence (AI) solutions that provide doctors and pharmacists with life-saving insights into patients’ healthcare by unlocking critical information buried within the free text of clinical notes. Savana’s SaaS platform leads the world in its field with over 400 million Electronic Medical Records processed in English, Spanish, German and French. Founded in 2014 in Spain, the company’s industry-leading technologies and services have been adopted by health systems across Western Europe, the United States and Canada.
Recommended AI News: MomentFeed Brings Four Major Proximity Discovery Innovations to Market
The new financing will be used to support Savana’s international expansion and operations in the US. Savana’s team is currently composed of 100+ professionals and over the next year the team at Savana’s headquarters in New York City is expected to grow by between 20 to 30 people. Savana already works with the top 20 pharmaceutical companies in the world and more than a hundred healthcare facilities.
“Savana’s potential positive impact on society is massive. Our mission is to predict the occurrence of disease at the patient level. This focuses our resources on discovering new ways of providing medical knowledge almost in real time – which is more urgent than ever in the context of the pandemic. Healthcare challenges are increasingly global, and we know that the application of AI across health data at scale is essential to accelerate health science. Cathay Innovation’s expertise in healthcare and track record in bridging continents for digital health technologies is remarkable, and we look forward to working with them to expand our global network,” said Savana’s CEO Jorge Tello.
Recommended AI News: Earnix Expands Its Boston Office and Welcomes Two New Hires
“Savana is a company founded by doctors for doctors. While we are rooted in technology, the clinical focus and ethics in the healthcare field remain at the core of our approach. One of our main value propositions is that the information remains controlled by the hospital, with privacy guaranteed by the de-identification of patient data before we process it,” said Dr Ignacio Hernandez Medrano, Co-Founder & CMO of Savana.
“Savana’s transformative technologies and solutions bring such incredible value to the medical space, that they are bound for widespread and mainstream adoption across the world. Now more than ever, advancements in the digital health sector is of the utmost importance and a major focus for Cathay Innovation, demonstrated by several investments and our recently sealed partnership with Sanofi. With a global network of experts and partners across North America, Europe and Asia, we’re looking forward to joining efforts with Savana’s talented team to accelerate the company further on the global stage and emerge as a leader in the AI HealthTech market,” said Jacky Abitbol, Partner of Cathay Innovation.
“We believe that innovators like Savana will play a key role in improving the healthcare industry in the coming years by applying the latest technologies. We are proud to continue partnering with such an ambitious project,” said Antonio Giménez de Córdoba, Partner at Seaya Ventures.
Recommended AI News: New Study Shows Brands Overlook Human Touch in Drive for Resilience